NATCO Pharma Ltd.
NSE: NATCOPHARM · Pharmaceuticals
Snapshot
Unlock NATCO Pharma Ltd.'s vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
NATCO Pharma Limited is a pharmaceutical company that develops, manufactures, and markets finished dosage formulations and active pharmaceutical ingredients (APIs). The company specialises in complex therapeutic areas, particularly oncology, gastroenterology, and cardiology, while providing contract manufacturing services globally.
Business Model
The company generates revenue through the sale of specialised pharmaceutical formulations and APIs across domestic and international markets. It leverages a diversified portfolio of chronic care drugs and contract manufacturing capabilities to maintain its market position.
Growth Outlook
Growth is driven by the expansion of its oncology and chronic disease product portfolios across approximately 40 countries. The company continues to focus on high-barrier-to-entry segments and international market penetration.
Key Risks
- Regulatory Compliance. The company faces significant risks related to stringent inspections and quality standards imposed by international health authorities like the US FDA.
- Pricing Pressure. Intense competition in the generic pharmaceutical sector and government-mandated price controls in India may impact profit margins.
- Litigation Risk. As a manufacturer of complex generic drugs, the company is exposed to potential patent litigation and intellectual property challenges from innovator pharmaceutical firms.
- Supply Chain Dependency. Reliance on external suppliers for raw materials and APIs could lead to operational disruptions if global supply chains are constrained.
Start your research today
Unlock AI insights, financials, peers and live data on NATCO Pharma Ltd. and 5,000+ companies — free.
Key Metrics
REVENUE
₹3,485 Cr
TTM · consolidated
NET PROFIT
₹1,145 Cr
TTM · consolidated
EPS
₹63.89
TTM · consolidated
RETURN ON EQUITY
13.6%
TTM · consolidated
RETURN ON CAPITAL EMPLOYED
13.5%
TTM · consolidated
P/E
13.0x
Q1 FY27 · consolidated
EV/EBITDA
11.4x
Q1 FY27 · consolidated
EBITDA MARGIN
38.7%
TTM · consolidated
NET PROFIT MARGIN
28.1%
Q1 FY27 · consolidated
DEBT TO EQUITY
0.1x
Q1 FY27 · consolidated
Peers · Pharmaceuticals
| Company | Mkt Cap | P/E | EV/EBITDA | Rev Gr YoY | EBITDA Mgn | ROE | ROCE | 1Y Return |
|---|---|---|---|---|---|---|---|---|
NATCO Pharma Ltd.NATCOPHARM | ₹14,842 Cr | 12.97 | 11.39 | -20.7% | 38.7% | 13.6% | 13.5% | -3.1% |
Alembic Pharmaceuticals Ltd.APLLTD | ₹15,886 Cr | 22.91 | 13.84 | 14.1% | 15.8% | 12.7% | 14.3% | -15.8% |
Sudeep PharmaSUDEEPPHRM | ₹15,014 Cr | 80.76 | 57.82 | — | 38.7% | 20.8% | 25.3% | — |
Concord Biotech Ltd.CONCORDBIO | ₹14,825 Cr | 54.32 | 33.68 | -6.7% | 39.7% | 14.2% | 18.5% | -15.1% |
Marksans Pharma LimitedMARKSANS | ₹14,811 Cr | 28.64 | 17.41 | 57.4% | 25.7% | 31.9% | 39.6% | +90.4% |
Jubilant Pharmova Ltd.JUBLPHARMA | ₹14,726 Cr | 41.59 | 12.91 | 16.3% | 15.0% | 5.3% | 6.5% | -13.2% |
As of Q1 FY27
Financials
NATCO Pharma Ltd.
NSE: NATCOPHARM · Pharmaceuticals
Snapshot
Unlock NATCO Pharma Ltd.'s vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
NATCO Pharma Limited is a pharmaceutical company that develops, manufactures, and markets finished dosage formulations and active pharmaceutical ingredients (APIs). The company specialises in complex therapeutic areas, particularly oncology, gastroenterology, and cardiology, while providing contract manufacturing services globally.
Business Model
The company generates revenue through the sale of specialised pharmaceutical formulations and APIs across domestic and international markets. It leverages a diversified portfolio of chronic care drugs and contract manufacturing capabilities to maintain its market position.
Growth Outlook
Growth is driven by the expansion of its oncology and chronic disease product portfolios across approximately 40 countries. The company continues to focus on high-barrier-to-entry segments and international market penetration.
Key Risks
- Regulatory Compliance. The company faces significant risks related to stringent inspections and quality standards imposed by international health authorities like the US FDA.
- Pricing Pressure. Intense competition in the generic pharmaceutical sector and government-mandated price controls in India may impact profit margins.
- Litigation Risk. As a manufacturer of complex generic drugs, the company is exposed to potential patent litigation and intellectual property challenges from innovator pharmaceutical firms.
- Supply Chain Dependency. Reliance on external suppliers for raw materials and APIs could lead to operational disruptions if global supply chains are constrained.
Start your research today
Unlock AI insights, financials, peers and live data on NATCO Pharma Ltd. and 5,000+ companies — free.
Key Metrics
REVENUE
₹3,485 Cr
TTM · consolidated
NET PROFIT
₹1,145 Cr
TTM · consolidated
EPS
₹63.89
TTM · consolidated
RETURN ON EQUITY
13.6%
TTM · consolidated
RETURN ON CAPITAL EMPLOYED
13.5%
TTM · consolidated
P/E
13.0x
Q1 FY27 · consolidated
EV/EBITDA
11.4x
Q1 FY27 · consolidated
EBITDA MARGIN
38.7%
TTM · consolidated
NET PROFIT MARGIN
28.1%
Q1 FY27 · consolidated
DEBT TO EQUITY
0.1x
Q1 FY27 · consolidated
Peers · Pharmaceuticals
As of Q1 FY27